Velvet Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $500K

  • Investors
  • 3

Velvet Therapeutics General Information

Description

Developer of gene therapies intended to treat rare cancers and autoimmune diseases using a proprietary platform. The company's gene therapies are a result of research, development, and commercialization of supercoiled DNA minicircles for the transfer of DNA into primary and stem cells, enabling researchers to get better transfection efficiencies and long-term effects and also that are easily delivered for safer, effective gene and cell therapies.

Contact Information

Formerly Known As
Twister Biotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2710 Reed Road
  • Suite 160
  • Houston, TX 77051
  • United States
+1 (713)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2710 Reed Road
  • Suite 160
  • Houston, TX 77051
  • United States
+1 (713)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Velvet Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 28-Aug-2023 $500K Completed Startup
1. Seed Round 11-Jan-2021 Completed Startup
To view Velvet Therapeutics’s complete valuation and funding history, request access »

Velvet Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Velvet Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Velvet Therapeutics Patents

Velvet Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4335924-A1 Ultrapure minivectors for gene therapy Inactive 08-Sep-2022
CA-3211307-A1 Utrapure minivectors for gene therapy Pending 08-Sep-2022
CA-3211300-A1 Using minivectors to treat idiopathic pulmonary fibrosis Pending 07-Sep-2022
EP-4338755-A1 Using minivectors to treat idiopathic pulmonary fibrosis Inactive 07-Sep-2022
US-20250263694-A1 Conjugated composition and method for delivering a therapeutic nucleic acid sequence to a living cell Pending 13-May-2022 C12N15/11
To view Velvet Therapeutics’s complete patent history, request access »

Velvet Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Velvet Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
BCM Ventures Venture Capital Minority
Angel (individual) Minority
Angel (individual) Minority
To view Velvet Therapeutics’s complete investors history, request access »

Velvet Therapeutics FAQs

  • When was Velvet Therapeutics founded?

    Velvet Therapeutics was founded in 2013.

  • Where is Velvet Therapeutics headquartered?

    Velvet Therapeutics is headquartered in Houston, TX.

  • What is the size of Velvet Therapeutics?

    Velvet Therapeutics has 10 total employees.

  • What industry is Velvet Therapeutics in?

    Velvet Therapeutics’s primary industry is Drug Discovery.

  • Is Velvet Therapeutics a private or public company?

    Velvet Therapeutics is a Private company.

  • What is Velvet Therapeutics’s current revenue?

    The current revenue for Velvet Therapeutics is .

  • How much funding has Velvet Therapeutics raised over time?

    Velvet Therapeutics has raised $1.62M.

  • Who are Velvet Therapeutics’s investors?

    BCM Ventures, , and have invested in Velvet Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process